Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2025/10/096537
CTRI/2025/10/096537
Not yet recruiting
Phase 2

A clinical study to assess the efficacy of test products in improving biophysical properties of skin upon face cleansing.

Hindustan Unilever Limited1 site in 1 country96 target enrollmentStarted: November 7, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Not yet recruiting
Enrollment
96
Locations
1
Primary Endpoint
Improvement in Brightness, Hydration
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

Volunteers are recruited based on inclusion and exclusion criteria and undergo 3 days of washout period. On Day 1 baseline (technical & dermatological) assessments are done. Volunteers and provided with face cleansers to apply on  the face at the venue. There are 4 test groups in the study with different wash frequencies per day. Volunteers apply the product for 3 consecutive days and all assessments done post wash. All technical and dermatological visual assessments were compared vs baseline.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant, Investigator and Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 45.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • •Healthy female volunteers 2)Volunteers with dull skin 3)Volunteers with dark spots 4)Volunteer in good health condition as per the medical screening criteria 5)Volunteer able to read, understand and sign an appropriate informed consent form indicating her willingness to participate.
  • •Volunteers agreeing to comply with following study restrictions: 7)Willing to refrain from application of any other product/treatment on their face during wash off and treatment phase 8)Not to apply any cosmetic, skin care product or home remedies or any other face cleanser/wash/soap etc at home during the study period.

Exclusion Criteria

  • •Volunteer pregnant or planning to become pregnant.
  • •Volunteers who are breastfeeding or having stopped to breastfeed in the past three months.
  • •Volunteers with any signs of significant local irritation, erythema or skin disease on scalp as well as on the visible parts of the body skin site.
  • •Volunteers having chronic illness or had major surgery in the last year.
  • •Volunteers undergoing any treatment of any skin condition on body.
  • •Volunteers known to have allergies to cosmetics 7)Volunteers taking any food supplements.

Outcomes

Primary Outcomes

Improvement in Brightness, Hydration

Time Frame: Baseline, Day 1, Day 2, Day 3

Secondary Outcomes

  • Safety assessments like redness and dryness(Baseline, Day 1, Day 2, Day 3)

Investigators

Sponsor Class
Other [Personal Care or Beauty Industry]
Responsible Party
Principal Investigator
Principal Investigator

Dr Niharika Salian

MASCOT-SPINCONTROL India Pvt. Ltd.

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.
2023-509969-20-00Celgene Corp.127
Not yet recruiting
Phase 2
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.
2024-511993-55-00Cosmo Technologies Limited120
Recruiting
Phase 2
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
NCT07353723Tang-Du Hospital10
Not yet recruiting
Not Applicable
A study to compare and find the better option for treatment of keloids between laser with injection or injection alone.
CTRI/2025/10/095881Dr Chetan Turale38
Recruiting
Phase 4
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.
2023-506602-39-00Universitair Medisch Centrum Utrecht310